therapies for patients who progress on jak inhibitors: imetelstat, navtemadlin, selinexor & tp-3654
Published 1 year ago • 165 plays • Length 3:13Download video MP4
Download video MP3
Similar videos
-
2:04
novel therapies for myelofibrosis patients who have failed jak inhibitors
-
1:25
combination approaches for the treatment of mf patients who progress after jak inhibitor therapy
-
2:09
approved & emerging jak inhibitors for patients with high-risk mf who are transplant-ineligible
-
0:53
investigating the place of jak inhibitors in the treatment of myelofibrosis
-
3:23
myelofibrosis: updates on jak inhibitors
-
3:19
therapeutic options following failure to jak inhibitors
-
0:46
xport-mf-034: selinexor plus ruxolitinib in jak-inhibitor naïve myelofibrosis
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
2:52
jak inhibitor combination therapy for the treatment of myelofibrosis
-
4:42
the role of jak inhibitors in treating mpns and the need for disease-modifying agents
-
3:21
looking beyond jak inhibitors: novel targeted therapies and strategies for mpn treatment
-
1:39
treating patients with myelofibrosis who are intolerant to or develop resistance to jak inhibitors
-
3:35
new phase iii trial of imetelstat versus bat in jak inhibitor-refractory myelofibrosis
-
1:23
targeted therapies beyond jak inhibitors
-
2:23
factors to consider when selecting jak inhibitors for patients with mf
-
2:47
analysis of jak inhibitors and risk of secondary b-cell lymphomas in mpn patients
-
1:53
ruxolitinib and jak inhibitors prior to transplantation
-
1:22
managing cytopenias following jak inhibitor treatment & achieving true disease modification in mf
-
2:00
xpo1 inhibition with selinexor for rrmm